Risk Factors for Pre-CAR-T Attrition Among Large B-Cell Lymphoma (LBCL) Patients

Natalie Wuliji(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Andrew J. Portuguese(University of Washington), Jordan Gauthier(Seattle Cancer Care Alliance), Erik L. Kimble(University of Washington), Marco Mielcarek(Fred Hutch Cancer Center), David G. Maloney(Fred Hutch Cancer Center), Rahul Banerjee(University of Washington), Aude G. Chapuis(University of Washington), Albert C. Yeh(University of Washington), Brian G. Till(University of Washington), Alexandre V. Hirayama(University of Washington), Mazyar Shadman(University of Washington), Christina Poh(University of Washington), Lorenzo Iovino(University of Pisa), Folashade Otegbeye(University Hospitals of Cleveland), Aya Albittar(University of Washington), Meredith Durbin, Mengyang Di(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ryan D. Cassaday(University of Washington), Chaitra S. Ujjani(Fred Hutch Cancer Center), Emily C. Liang(Fred Hutch Cancer Center), Lisa Getzendaner(Fred Hutch Cancer Center), Stephen D. Smith(Seattle Cancer Care Alliance), Katherine Gieseke(Fred Hutch Cancer Center), Lilan Tang-Dizon(Fred Hutch Cancer Center), Hannah Alo(Fred Hutch Cancer Center), Aliscia Kemennu(Fred Hutch Cancer Center), Kathryn Buckman(Washington State University), Mahnoosh Taheri(Washington State University), Jennifer J. Huang(Stanford Medicine), Vikram Raghunathan, Krystle Peterson(Fred Hutch Cancer Center), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Courtney Sanderson(Fred Hutch Cancer Center), Ryan C. Lynch(Seattle Cancer Care Alliance)
Transplantation and Cellular Therapy
February 1, 2024
10.1016/j.jtct.2023.12.505
Cited by 2

Related Papers

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
|Blood|2008|719
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603